Peptinov

Pre-clinical

Paris, FranceFounded 2011peptinov.fr

Peptinov is a clinical-stage biotech focused on discovering and developing novel peptide drugs for chronic inflammatory diseases. The company's lead candidate, P1, is in Phase 1/2 development for systemic sclerosis, targeting a novel mechanism to address fibrosis. Peptinov's technology platform enables the rational design of peptides with enhanced stability and specificity, aiming to overcome limitations of traditional biologics and small molecules in inflammatory disorders.

Founded

2011

Employees

11-50

Focus

RNA & Gene Therapy

AI Company Overview

Technology Platform

Proprietary peptide design and optimization platform for developing therapeutic peptides with enhanced stability, specificity, and pharmacokinetic properties targeting inflammatory pathways.

Funding History

Total raised: $2.5M

Seed$2.5MUndisclosedMar 15, 2021

Opportunities

Significant unmet need in systemic sclerosis and other fibrotic diseases creates substantial market opportunity.

Growth potential through platform expansion into additional autoimmune indications and potential for partnership deals with larger pharma companies.

Risk Factors

Clinical development risk for lead candidate, competition from established and emerging therapies, dependence on additional financing, and technical challenges in peptide drug development.

Competitive Landscape

Faces competition from large pharma with approved therapies for systemic sclerosis and numerous biotechs developing novel approaches. Differentiation through proprietary peptide platform and focus on novel targets within inflammatory pathways.